Effectiveness of the IP2 on cardio-metabolic risk factors of type2 diabetes (pre-post analysis)
GLMM results indicate that diastolic BP was significantly lower in the evaluation phase than baseline AβC = -4.09mmHq (95% CI: -5.42 to -2.76). Fasting blood glucose was significantly higher in the evaluation phase than the baseline phase AβC = 0.39mmol/L (95% CI: 0.23 to 0.55). After adjusting for the interaction between IP2 and age of the consumers, the BMI was significantly lower in the evaluation phase than baseline AβC = -0.7kg/m